You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,179,127


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,179,127 protect, and when does it expire?

Patent 10,179,127 protects OMLONTI and is included in one NDA.

This patent has forty-four patent family members in twenty-six countries.


Drugs Protected by US Patent 10,179,127

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Visiox Pharma OMLONTI omidenepag isopropyl SOLUTION;OPHTHALMIC 215092-001 Sep 22, 2022 DISCN Yes No ⤷  Subscribe ⤷  Subscribe Y METHOD OF TREATING OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN PATIENTS ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,179,127

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015205188 ⤷  Subscribe
Brazil 112016015763 ⤷  Subscribe
Canada 2936026 ⤷  Subscribe
Chile 2016001756 ⤷  Subscribe
China 105899209 ⤷  Subscribe
China 108743587 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.